Chinook Therapeutics Announces Upcoming Encore Presentations at ISN World Congress of Nephrology 2022

SEATTLE, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc.,  (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the ISN World Congress of Nephrology 2022 from February 24 – 27, 2022.

The following abstracts will be presented as poster presentations at the ISN World Congress of Nephrology 2022:

Abstract WCN22-0484     A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
Author:     Hiddo J. L. Heerspink, PhD, PharmD, University Medical Center Groningen, Groningen, Netherlands
Abstract WCN22-0480     Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study)
Author:     Anjay Rastogi, MD, PhD, UCLA David Geffen School of Medicine, Los Angeles, CA
Abstract WCN22-0485      Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Phase 1/2 Trial
Author:     Jonathan Barratt, MChB, PhD, FRCP, University of Leicester, Leicester, UK
Abstract WCN22-0483     ADU-CL-19: A Phase 1/2, Multicenter Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy
Author:     Jonathan Barratt, MChB, PhD, FRCP, University of Leicester, Leicester, UK
For more information on these and other abstracts, please visit the ISN World Congress of Nephrology 2022 website.

About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. In addition, Chinook is advancing CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit

Noopur Liffick
Vice President, Investor Relations & Corporate Communications 

Primary Logo

Back to news